
CAS
210826-40-7
Formulation
A crystalline solid
Purity
≥98%
MW
404,5
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
An inhibitor of NLRP3 inflammasome activation; inhibits ATP-induced IL-1β release in LPS-primed mouse BMDMs (IC50 = 7.5 nM), as well as cytosolic LPS-induced IL-1β release in Pam3CSK4-primed mouse BMDMs at 0.1 and 1 µM; selective for NLRP3 over NLRC4 and AIM2 inflammasomes and does not inhibit LPS-induced NLRP3 priming in mouse BMDMs at 10 µM; reduces ox-LDL-induced increases in caspase-1 activity and inhibits pyroptosis in THP-1 macrophages at 1 µM; reduces myocardial fibrosis in mice following myocardial infarction induced by left coronary artery ligation at 10 mg/kg; improves forelimb grip strength and reduces spinal edema in a mouse model of spinal crush injury at 10 mg/kg
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).